申请人:Janssen Pharmaceutica N.V.
公开号:EP3354651A1
公开(公告)日:2018-08-01
The present invention comprises compounds of Formula I.
wherein:
X, A1, A2, A3, A4, R1, R2, and R3 are defined in the specification.
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORyt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.
本发明包括式 I 的化合物。
其中
X、A1、A2、A3、A4、R1、R2 和 R3 在说明书中定义。
本发明还包括一种治疗或改善综合征、紊乱或疾病的方法,其中所述综合征、紊乱或疾病为类风湿性关节炎或银屑病。本发明还包括一种通过施用治疗有效量的至少一种权利要求 1 的化合物来调节哺乳动物体内 RORyt 活性的方法。